Aethlon Medical & North Immunology Announce Merger. Stock Soars 370% in Pre-Market

Aethlon Medical, Inc. (Nasdaq: AEMD) announced a definitive all-stock merger agreement with North Immunology, Inc., a privately held biotechnology company developing bispecific antibodies for immune and inflammatory diseases.

The combined company plans to advance NOR-101, a potentially best-in-class, half-life-extended IL-13 x IL-18 bispecific antibody being developed for atopic dermatitis and other immune-mediated diseases.

Alongside the merger, North Immunology is expected to receive approximately $180 million in gross proceeds through a private placement backed by healthcare-focused institutional investors. The funding is expected to support operations into the second half of 2028.

Following completion of the transaction, the combined company will operate as North Immunology, Inc. and is expected to trade on the Nasdaq Capital Market under the ticker NRTX. PRNewswire reports.

🧭 Dow, S&P 500, Nasdaq Rise as Fed Rate Hike Pacifies Markets' Inflation Worries

US stocks rose in premarket trading Thursday as oil prices moved lower and investors assessed the Federal Reserve's latest policy decision. Dow Jones Industrial Average futures gained 0.7%, S&P 500 futures rose 0.7%, and Nasdaq-100 futures advanced 0.8%.

The Federal Reserve raised interest rates by 25 basis points on Wednesday, marking its first rate hike in three years, and projected one additional increase this year. Markets rebounded as investors weighed Fed Chair Kevin Warsh's comments and the central bank's focus on containing inflation.

Oil prices also declined as concerns around supply disruptions eased. Brent crude traded near $104 per barrel as attention turned to efforts to restore capacity on Saudi Arabia's East-West pipeline. Yahoo Finance reports.

🧬 DataMeds Completes Helomics AI Acquisition. Stock Up in Pre-Market

DataMeds AI (NASDAQ: MEDS) shares surged in pre-market trading after the company completed its acquisition of Helomics, an AI-powered cancer diagnostics laboratory and precision oncology contract research organization (CRO).

The stock moved above several key moving averages as investors reacted to the acquisition, accelerating its upward momentum on September 16.

Despite rising more than fivefold during the session, DataMeds AI shares remain approximately 60% below their level at the start of 2026. Invezz reports.

👓 Why Is Snap Stock Trading Higher on Thursday?

Snap Inc. (NYSE: SNAP) shares rose about 3% in Thursday pre-market trading after the company announced new enterprise partnerships aimed at expanding use cases for its SPECS augmented reality glasses.

Snap announced partnerships with Salesforce Inc. (NYSE: CRM), Nvidia Corp. (NASDAQ: NVDA), and Amazon Web Services, part of Amazon.com Inc. (NASDAQ: AMZN).

The stock also benefited from broader market strength, with S&P 500 futures up about 0.9%. SNAP had already gained more than 4% in after-hours trading on Wednesday. Benzinga reports.

🏭 Why Generac Shares Are Trading Higher By Around 35%

Generac Holdings Inc. (NYSE: GNRC) shares surged in pre-market trading after the company announced a long-term supply agreement with Amazon.com Inc. (NASDAQ: AMZN) for backup generators used at Amazon data centers.

The agreement is valued at up to $8 billion, with initial generator deliveries expected to total approximately $2.4 billion across 2027 and 2028.

Generac shares jumped 34.8% to $235.90 in pre-market trading following the announcement. Benzinga reports.

🤖 Apollo Mulls Raising SoftBank Loan to $9 Billion for OpenAI Bets

Apollo Global Management Inc. is reportedly in talks with SoftBank Group Corp. to increase the size of an existing loan from $5.4 billion to as much as $9 billion, potentially giving SoftBank additional capital to expand its investments in OpenAI.

The financing is backed by assets in SoftBank's Vision Fund 2, although the final size has not yet been determined. Representatives for Apollo and SoftBank declined to comment on the discussions.

Apollo originally provided the net-asset-value loan to SoftBank's venture capital fund in 2021 and increased it by $900 million last year to $5.4 billion. NAV loans allow investment firms to borrow against the value of assets held within a fund. Yahoo Finance reports.

(All pricing and percent gains are based on Early Pre-Market from 4:00 AM to 7:00 AM ET). Stock Analysis reports.

1) AEMD: Aethlon Medical, Inc.
Total gain: +434.97%

2) DAIC: CID HoldCo, Inc.
Total gain: +111.94%

3) AEHL: Antelope Enterprise Holdings Limited
Total gain: +37.74%

4) GNRC: Generac Holdings Inc.
Total gain: +31.92%

5) LRHC: La Rosa Holdings Corp.
Total gain: +10.61%

The closing price of the top three market percent gainers trading near or above $2 on Sep 16.

(All pricing and percent gains are based on regular market trading hours from 9:30 AM to 4:00 PM ET). Stock Analysis reports.

1) MEDS: DataMEDS AI, Inc.
Total gain: +274.69%

The company announced it completed the acquisition of Helomics Corporation ("Helomics"), an artificial intelligence cancer diagnostics laboratory business, from Axe Compute Inc. (NASDAQ:AGPU) ("Axe Compute" or the "Company"), a neocloud AI infrastructure platform. AccessNewswire reports.

2) AEHL: Antelope Enterprise Holdings Limited
Total gain: +78.68%

The company announced the closing of its previously announced offering of 8.00% convertible promissory notes in an aggregate principal amount of $6.0 million (the “Note”) to an accredited investor. The Company received net proceeds from the offering of the Note of approximately $5.965 million, after deducting estimated offering expenses. GlobeNewswire reports.

3) NAMI: Jinxin Technology Holding Company
Total gain: +36.84%

The company announced an agreement to acquire economic interests tied to 40% of Yuanwei Network Technology, expanding its exposure to AI-generated video, short-form content and micro-drama production and distribution. PRNewswire reports.

Estimate and Actual numbers represent Earnings Per Share in US Dollars.

YI

111

Q2 2026

After Market Close

Estimate: N/A

Actual: -0.600

IPHA

Innate Pharma
H1 2026

After Market Close

Estimate: -0.160
Actual: -0.244

UPXI

Upexi

Q4 2026

After Market Close

Estimate: -0.110

Actual: N/A

Time (ET) / Report / Period

• 8:30 AM / Housing Starts / Aug.
• 8:30 AM / Philadelphia Fed Business Outlook Survey / Sep.
• 8:30 AM / Weekly Jobless Claims / Sept. 12

“The essence of investment management is the management of risks, not the management of returns.”

— Benjamin Graham

Sourced in Shell Capital.

TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas ; TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF); and TradeZero Europe B.V., a Dutch broker dealer, authorized and regulated by the Dutch Authority for the Financial Markets (AFM) (collectively, the “TradeZero Broker Dealers”).

TradeZero Broker Dealers offer self-directed electronic securities trading to their customers. TradeZero Broker Dealers do not provide financial or trading advice and do not make investment recommendations to their customers. This communication does not constitute an offer to sell or a solicitation to buy any security or instrument which it may reference.

The information in this newsletter summarizes the latest market activity and related news and are provided for educational purposes only. Any trading symbols displayed are for illustrative purposes only and do not constitute a recommendation by TradeZero to buy, sell, or hold any investment. This material is not intended to provide investment advice or to take into account any individual’s financial condition, investment objectives, or requirements.

Investing involves risk, including the possible loss of principal.

There is a risk of loss in online trading of securities including equities and options. Trading on margin is for experienced investors whereby the loss can be greater than your initial investment. Likewise, short selling as a securities trading strategy is extremely risky and can lead to potentially unlimited losses.

Options trading is not suitable for all investors as it can involve risk that may expose investors to significant losses. Please read the Characteristics and Risks of Standardized Options, also known as the Options Disclosure Document (ODD) at OCC.

Stocks experiencing significant price volatility may involve substantial risk. Past performance is no guarantee of future results.

Any trading strategies discussed are for educational purposes only and should not be construed as investment advice or a recommendation.

Certain information herein has been obtained from third-party sources believed to be reliable; however, its accuracy or completeness cannot be guaranteed. The views and opinions expressed are those of the author and do not necessarily reflect the views or opinions of TradeZero, its affiliates, or employees.

If you have any specific questions about TradeZero's brokerage services, please reach out to the TradeZero Broker Dealer servicing your jurisdiction.

Copyright © TradeZero 2026. All rights reserved.